» Articles » PMID: 20694405

[GADA Persistence and Detectable C Peptide in Patients with Long Standing Diabetes Mellitus Type 1]

Overview
Specialty Endocrinology
Date 2010 Aug 10
PMID 20694405
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The aim of this study was to evaluate if GADA+ and detectable CP had any influence in other autoimmune diseases, glycemic control, and risks of retinopathy in diabetes mellitus type 1 (T1DM) lasting longer than 3 years of duration.

Subjects And Methods: Fifty T1DM subjects were interviewed, performed fundoscopic examination, and measured CP before and after glucagon, HbA1C, and GADA.

Results: GADA+ (n = 17) had a higher frequency of other autoimmune diseases when compared to GADA (p = 0.02). Detectable CP was also associated with a higher prevalence of these diseases (p = 0.03), although, retinopathy was not influenced by either one. Detectable CP had no influence in the glycemic control (mean HbA1C) (p = 0.28). However, insulin daily doses were lower in this group (0.62 vs. 0.91 U/kg/day; p = 0.004).

Conclusion: Although not recommend as a marker of other autoimmune diseases, GADA+ seems to be not only a pancreatic autoimmunity signal. Detectable CP may also have some promising influence in detecting these diseases. Neither influenced the presence of retinopathy, but insulin daily requirements were smaller when CP was present.

Citing Articles

Relationship Between C-Peptide Levels, Clinical Features, and Serum Data in a Brazilian Type 1 Diabetes Population with Large Variations in Genomic Ancestry.

Azulay R, Rodrigues V, Lago D, Almeida A, de Abreu J, Matos L Int J Mol Sci. 2024; 25(20).

PMID: 39456927 PMC: 11508759. DOI: 10.3390/ijms252011144.


Prevalence of diabetic retinopathy in Brazil: a systematic review with meta-analysis.

Chagas T, Dos Reis M, Leivas G, Santos L, Gossenheimer A, Melo G Diabetol Metab Syndr. 2023; 15(1):34.

PMID: 36864478 PMC: 9979496. DOI: 10.1186/s13098-023-01003-2.